Rankings
Publications
Sources
Publishers
Scholars
Organizations
About
Login
Register
Home
Publications
Similar outcome of elderly patients in Intergroup Trial 0096
Home
Publications
Similar outcome of elderly patients in Intergroup Trial 0096
Similar outcome of elderly patients in Intergroup Trial 0096
Alan R. Yuen
Alan R. Yuen
GZ
Guangyong Zou
Guangyong Zou
AT
Andrew T. Turrisi
Andrew T. Turrisi
WS
William Sause
William Sause
RK
Ritsuko Komaki
Ritsuko Komaki
HW
Henry Wagner
Henry Wagner
SA
Seena C. Aisner
Seena C. Aisner
RL
Robert B. Livingston
Robert B. Livingston
RB
Ronald Blum
Ronald Blum
DJ
David H. Johnson
David H. Johnson
Publisher Website
Google Scholar
Add to library
Cite
Download
Share
Download
1 November 2000
journal article
Published by
Wiley
in
Cancer
Vol. 89
(9)
,
1953-1960
https://doi.org/10.1002/1097-0142(20001101)89:9<1953::aid-cncr11>3.3.co;2-y
Abstract
BACKGROUND Elderly patients comprise a significant portion of patients with limited stage small cell lung carcinoma. However, the prognostic importance of age has been controversial, and concern for toxicity often hinders enthusiasm for offering full dose therapy. METHODS In this retrospective analysis of Intergroup Trial 0096, the authors compared the outcome of patients 70 years or older to those younger than 70 years. Patients received cisplatin 60 mg/m
2
, Day 1 and etoposide 120 mg/m
2
, Days 1–3 for 4 cycles and either once or twice daily concurrent thoracic radiotherapy to 45 grays. RESULTS Of 381 patients, 50 (13%) were age 70 years or older. The elderly group did not differ significantly from those younger than 70 years with respect to gender distribution, performance status, or weight loss. Severe hematologic toxicity (Grade 4–5: 61% vs. 84%;
P
< 0.01) and fatal toxicity (1% vs. 10%;
P
= 0.01) occurred more often among older patients. There were no differences in the frequency of nonhematologic toxicities. Response rate (88% vs. 80%;
P
= 0.11), event free survival rate (5 year, 19% vs. 16%;
P
= 0.18), time to local failure, and duration of response did not differ between groups. Overall survival rates (5 year, 22% vs. 16%;
P
= 0.05) favored those younger than 70 years. Much of the difference in overall survival rates between age groups occurred within the first 6 months on study. CONCLUSIONS Elderly patients had similar response and survival rates compared with those younger than 70 years. However, toxicity, particularly hematologic, was greater among the elderly. Selected older patients, such as those with a good performance status, should be considered for optimum treatment approaches. Cancer 2000;89:1953–60. © 2000 American Cancer Society.
Keywords
LUNG
SMALL CELL LUNG CARCINOMA
ELDERLY
RADIATION THERAPY
CHEMOTHERAPY
All Articles
Open Access
Cited by 102 articles